Eli Lilly and Company (LLY)
$
732.58
+0.62 (0.08%)
Key metrics
Financial statements
Free cash flow per share
2.0198
Market cap
693.4 Billion
Price to sales ratio
13.0188
Debt to equity
1.8705
Current ratio
1.2777
Income quality
0.7926
Average inventory
10.2 Billion
ROE
0.8836
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Eli Lilly and Company, established in 1876 and headquartered in Indianapolis, Indiana, discovers, develops, and markets human pharmaceuticals globally. The total costs and expenses for the company are $27,541,000,000.00 reflecting its overall spending on research, development, and various operational activities. The operating income ratio is 0.39 indicating the company's operational profitability margin, showcasing its capacity to manage costs in relation to income generated. Its operational expenses amount to $19,122,700,000.00 encompassing the various costs incurred in pursuing its business objectives. Additionally, the gross profit ratio is 0.81 reflecting the efficiency of the company's production and sales operations amid its diverse product portfolio, which includes treatments for diabetes, various cancers, autoimmune conditions, and mental health disorders. Notable products such as Basaglar, Humalog, Jardiance, Alimta, and Taltz emphasize Lilly's broad impact across multiple therapeutic areas. The diluted EPS is $11.71 accounting for potential share dilution, which is an essential consideration for investors assessing the company's financial health and profitability. In the financial markets, the stock is priced at $799.34 positioning it in the higher-end market and reflecting investor confidence. It has a high average trading volume of 4,391,866.00 indicating strong liquidity that is desirable for both retail and institutional investors. With a large market capitalization of $693,355,469,060.00 the company is a dominant player in the pharmaceutical space, influencing trends and developments within the industry. Eli Lilly is a key player in the Drug Manufacturers - General industry, contributing significantly to the overall market landscape through innovative therapies and clinical advancements. Furthermore, it belongs to the Healthcare sector, driving innovation and growth while collaborating with various pharmaceutical and biotechnology firms, which strengthens its position in a competitive environment. The combination of a robust product portfolio and a strategic focus on emerging therapies places Eli Lilly in a favorable position for future success while continuing to meet the evolving needs of patients across the globe.
Is Eli Lilly and Company (LLY) a good investment?
Investing in Eli Lilly and Company (LLY) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
What is Eli Lilly and Company (LLY)'s stock forecast?
Analysts predict Eli Lilly and Company stock to fluctuate between $623.78 (low) and $969.65 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Eli Lilly and Company's market capitalization?
As of 2025-08-29, Eli Lilly and Company's market cap is $693,355,469,060, based on 946,457,000 outstanding shares.
How does Eli Lilly and Company compare to competitors like Johnson & Johnson?
Compared to Johnson & Johnson, Eli Lilly and Company has a Higher Market-Cap, indicating a difference in performance.
Does Eli Lilly and Company pay dividends?
Eli Lilly and Company pays dividends. The current dividend yield is 0.83%, with a payout of $1.50 per share.
How can I buy Eli Lilly and Company (LLY) stock?
To buy Eli Lilly and Company (LLY) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LLY. Place an order (Market, Limit, etc.).
What is the best time to invest in Eli Lilly and Company?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Eli Lilly and Company stock ever split?
Eli Lilly and Company's last stock split was 2:1 on 1997-10-16.
How did Eli Lilly and Company perform in the last earnings report?
Revenue: $45,042,700,000 | EPS: $11.76 | Growth: 101.72%.
Where can I find Eli Lilly and Company's investor relations reports?
Visit https://www.lilly.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Eli Lilly and Company?
You can explore historical data from here
What is the all-time high and low for Eli Lilly and Company stock?
All-time high: $972.53 (2024-08-22) | All-time low: $220.20 (2021-09-28).
What are the key trends affecting Eli Lilly and Company stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
benzinga.com
Although the stock has experienced its fair share of turbulence in 2025, Eli Lilly LLY is rapidly emerging as a key consideration for investors seeking to hedge their portfolios away from tech and AI picks.
invezz.com
Eli Lilly has partnered with a leading Chinese tech company, JD Health to fast-track its presence in China's rapidly expanding obesity drug market, boosting the company's global growth in the weight-loss sector. Eli Lilly's move into the obesity drug market is reshaping the global pharma landscape.
benzinga.com
Trading is quiet in Eli Lilly and Co LLY on Thursday. The stock has stalled out at a resistance level.
fool.com
According to a filing with the Securities and Exchange Commission dated Aug. 12, 2025, Stevens Capital Management LP completely exited its position in Eli Lilly and Company (LLY -0.20%), by selling all 12,036 shares in Q2 2025.
proactiveinvestors.co.uk
Eli Lilly and Co (NYSE:LLY) has halted shipments of its Mounjaro diabetes and weight-loss drug to the UK ahead of a planned price hike next month. Earlier this week the US drug giant warned against "inappropriate stockpiling of medicines", as customers rushed to buy the drug ahead of a planned 170% price rise, where the highest dose of the medicine will increase from £122 to £330.
reuters.com
Eli Lilly has temporarily paused shipments of its weight-loss drug Mounjaro in the UK, ahead of a new price hike for the treatment set to come into effect starting next month.
marketwatch.com
The bear case for Eli Lilly has now played out following the reaction to the drugmaker's oral obesity drug trial, an analyst said Wednesday in upgrading the stock.
prnewswire.com
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year landmark analysis of monarchE, treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit Results reinforce two years of Verzenio plus endocrine therapy as the standard of care in HR+, HER2-, node-positive, early breast cancer at a high risk of recurrence INDIANAPOLIS , Aug. 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial. Treatment with two years of Verzenio plus endocrine therapy (ET) demonstrated a statistically significant and clinically meaningful improvement in OS compared to ET alone in patients with hormone receptor positive (HR+), HER2-, node-positive, high-risk early breast cancer.
youtube.com
Geoff Meacham, Citi Research Managing Director, joins 'Fast Money' to talk competition in the weight loss drug space as Eli Lilly's weight loss pill clears its latest trial.
investopedia.com
Major U.S. equities indexes ticked higher as investors looked past concerns about President Donald Trump's effort to remove Federal Reserve Governor Lisa Cook and ahead to Wednesday's Nvidia earnings release.
See all news
